Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer

Exploratory Evaluation Of A Sequential Administration Of Docetaxel And SU011248 In Women With Advanced Breast Cancer

This study is to evaluate the safety of SU011248 (Sunitinib/Sutent) in combination with docetaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.

Inclusion Criteria:

• Breast cancer with evidence of unresectable, locally recurrent or metastatic disease
• Candidate for treatment with docetaxel

Exclusion Criteria:

• Prior chemotherapy in the advanced disease setting
• Inflammatory breast cancer
• HER2 positive disease